Last reviewed · How we verify
Zebinix
Zebinix is a Small molecule drug developed by Centre Hospitalier Saint Joseph Saint Luc de Lyon. It is currently in Phase 2 development for Partial seizure. Also known as: Eslicarbazepine acetate (ESL).
Zebinix, also known as Eslicarbazepine acetate, is an anticonvulsant medication used to treat partial-onset seizures in epilepsy. It works by blocking the sodium channel alpha subunit, a mechanism that is classified as a small molecule blocker.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Zebinix |
|---|---|
| Also known as | Eslicarbazepine acetate (ESL) |
| Sponsor | Centre Hospitalier Saint Joseph Saint Luc de Lyon |
| Target | Sodium channel alpha subunit |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Approved indications
- Partial seizure
Common side effects
Key clinical trials
- Anti-epileptogenic Effects of Eslicarbazepine Acetate (PHASE2)
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate (PHASE1)
- Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization (PHASE1)
- A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers (PHASE1)
- Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine (PHASE1)
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (PHASE1)
- The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin (PHASE1)
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zebinix CI brief — competitive landscape report
- Zebinix updates RSS · CI watch RSS
- Centre Hospitalier Saint Joseph Saint Luc de Lyon portfolio CI
Frequently asked questions about Zebinix
What is Zebinix?
What is Zebinix used for?
Who makes Zebinix?
Is Zebinix also known as anything else?
What development phase is Zebinix in?
What does Zebinix target?
Related
- Target: All drugs targeting Sodium channel alpha subunit
- Manufacturer: Centre Hospitalier Saint Joseph Saint Luc de Lyon — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Partial seizure
- Also known as: Eslicarbazepine acetate (ESL)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing